Iran as the world’s 18th-most-populous country has passed 80 million in 2016 with its population growth rate of about 1.3. In 2013, it was reported that sixty percent of its population was under the age of 30. With an estimated Gross Domestic Product (GDP) in 2015 of 393.7 billion USD Iran is the second largest economy in the Middle East and North Africa (MENA) region. In addition, Iran has one of the largest capacity of production of generic medicines in the Middle East and MENA region. While per capita consumption of generic medicines is acceptable, access to specialized medicines for treatment of life threatening medicines is restricted due to limited resources available in health care system. Therefore, most imported medicines are including biotherapeutics, recombinants and oncology medicines. Of late, Iran MOH has announced its support for international investment into Iran pharmaceutical market. Iran plans to provide acceptable environment in order to attract foreign investment for pharmaceutical industry in order to upgrade its technology capabilities and manufacture high tech medicines such as mAbs and recombinant proteins.
In 2016, the number of active hospitals was 954 throughout the country which had been increased by 6% compared to 2015 and 80% of hospitals were state and only 20% was considered nongovernmental. According to the National Treatment Plan of Iran, by the year 1404, 73,000 new hospital beds will be added to the state hospitals and 40,000 will be added to the private hospitals. Furthermore, there have been established 59 medical schools in this country that provide state-of-the-art education services and train a considerable number of doctors, nurses and other healthcare experts annually. Based on key components such as expertise, standards in medical research and health care services and quite low treatment costs compared to its competitors in the Middle East, Iran is a potential hub for clinical researches.